OncoMatch/Clinical Trials/NCT04370925
Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis
Is NCT04370925 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Systemic chemotherapy for colorectal cancer.
Treatment: Systemic chemotherapy — The purpose of this study is to determine the efficacy of adjuvant HIPEC with Mitomycin C after colectomy in the treatment of colorectal cancer patients at high risk of peritoneal carcinomatosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage CT4N0-2M0 (AJCC 8th edition)
Intraoperative confirmed cT4N0-2M0 Colorectal cancer (visual determination - according to AJCC 8th edition) without previous anti-cancer treatment and R0 resection could be achieved
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Neutrophil ≥ 2.0 /mm3, platelets ≥ 100,000/mm3, hemoglobin≥90g/l
Kidney function
serum creatinine ≤ 1.5 ×ULN
Liver function
ALT and AST ≤ 2.5 ×ULN, total bilirubin(TBIL)≤ 1.5 × ULN
Laboratory tests within 2 weeks before Randomization：Neutrophil ≥ 2.0 /mm3, , platelets ≥ 100,000/mm3, hemoglobin≥90g/l, Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ×ULN), total bilirubin(TBIL)≤ 1.5 × ULN, serum creatinine ≤ 1.5 ×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify